StreetInsider.com News Articles

Esperion Therapeutics (ESPR) PT Raised to $5 at Citizens After Q4 Results

Fri, 13 Mar 2026 05:40:10 -0400

Citizens analyst Jason N. Butler raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $5.00 (from $4.00) while maintaining a Market Outperform rating.

The analyst commented, "NEXLETOL/NEXLIZET growth trajectory remains robust; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $5 from $4 on Esperion Therapeutics. Esperion reported 4Q25 financial results, consistent with the preannouncement in January. The company continues to execute its Vision 2040 plans underscored by the recent acquisition of Corstasis Therapeutics and ongoing pipeline expansion through advancement of ESP-2001. Year-end 2025 cash was ~$170MM and in our view the company is well

Esperion Therapeutics (ESPR) PT Raised to $5 at Citizens After Q4 Results

Fri, 13 Mar 2026 05:40:10 -0400

Citizens analyst Jason N. Butler raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $5.00 (from $4.00) while maintaining a Market Outperform rating.

Form 10-K Esperion Therapeutics, For: Dec 31

Tue, 10 Mar 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260310/26140349.html

Form 10-K Esperion Therapeutics, For: Dec 31

Tue, 10 Mar 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260310/26140349.html

H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR): "we expect continued growth"

Tue, 10 Mar 2026 12:17:02 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $16.00 price target on Esperion Therapeutics (NASDAQ: ESPR)

The analyst commented, "Well-established U.S. commercial development strategy and international footprint validate strong momentum for BDA; we expect continued growth during 2026. Real-world data support clinical efficacy and prescription volume; we anticipated forthcoming U.S. dyslipidemia treatment guidelines from ACC/AHA to strengthen BDA adoption. Vision 2040 growth strategy as a multiple blockbuster product company backed by: 1) recent Corstasis acquisition; 2) investigational triple combination BDA programs; and 3) early-stage next-gen ACLYi candidate (ESP-2001) for PSC... We maintain our Buy rating and $16 price target.

Form 8-K Esperion Therapeutics, For: Mar 10

Tue, 10 Mar 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260310/26135270.html

Form 8-K Esperion Therapeutics, For: Mar 10

Tue, 10 Mar 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260310/26135270.html

Esperion Therapeutics (ESPR) Misses Q4 EPS by 7c ; Provides Outlook

Tue, 10 Mar 2026 06:52:08 -0400

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of $0.22, $0.07 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $168.45 million versus the consensus estimate of $168.28 million.

2026 Financial Outlook

The Company expects full year 2026 operating expenses to be in the range of $225 million to $255 million, including approximately $15 million in non-cash expenses related to stock compensation.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 10 Mar 2026 06:00:00 -0400

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

– Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million –

– Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –

– Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) –

– Conference Call and Webcast Today at 8:00 a.m. ET –

ANN ARBOR, Mich., March 10,

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 10 Mar 2026 06:00:00 -0400

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

– Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million –

– Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –

– Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) –

– Conference Call and Webcast Today at 8:00 a.m. ET –

ANN ARBOR, Mich., March 10,

Form 8-K Esperion Therapeutics, For: Mar 02

Tue, 03 Mar 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260303/26096358.html

Form 8-K Esperion Therapeutics, For: Mar 02

Tue, 03 Mar 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260303/26096358.html

Esperion to acquire Corstasis for $75 million plus milestones

Tue, 03 Mar 2026 06:00:17 -0400

Esperion Therapeutics Inc. (NASDAQ: ESPR) announced it has entered into a definitive agreement to acquire Corstasis Therapeutics Inc., a privately-held biopharmaceutical company, for $75 million in cash upfront plus potential milestone payments of up to $180 million.

The acquisition will give Esperion ownership of Enbumyst (bumetanide nasal spray), which received FDA approval in September 2025 as the first nasal spray loop diuretic for treating edema associated with congestive heart failure, hepatic disease and renal disease in adults.

Under the transaction terms, Corstasis shareholders will also receive low double-digit royalties on worldwide sales of Enbumyst and follow-on products. The milestone payments are tied

Esperion to acquire Corstasis for $75 million plus milestones

Tue, 03 Mar 2026 06:00:17 -0400

Under the transaction terms, Corstasis shareholders will also receive low double-digit royalties on worldwide sales of Enbumyst and follow-on products. The milestone payments are tied

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Tue, 03 Mar 2026 06:00:00 -0400

– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –

– Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements –

– Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET –

ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Tue, 03 Mar 2026 06:00:00 -0400

– Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements –

– Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET –

ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Tue, 03 Mar 2026 06:00:00 -0400

– Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements –

– Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET –

ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Tue, 03 Mar 2026 06:00:00 -0400

– Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements –

– Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET –

ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

Tue, 24 Feb 2026 08:00:00 -0400

ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

Tue, 24 Feb 2026 08:00:00 -0400

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Wed, 18 Feb 2026 08:00:00 -0400

ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Wed, 18 Feb 2026 08:00:00 -0400

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated

Esperion settles with fifth generic drug maker over cholesterol patents

Tue, 17 Feb 2026 08:00:54 -0400

Esperion Therapeutics Inc. (NASDAQ: ESPR) reached a settlement agreement with Alkem Laboratories Ltd. to resolve patent litigation over generic versions of the company's cholesterol medications NEXLETOL and NEXLIZET.

Under the agreement announced February 17, Alkem agreed not to market generic versions of either drug in the United States before April 19, 2040, unless certain limited circumstances occur. The settlement resolves litigation that began after Alkem filed Abbreviated New Drug Applications seeking approval to market generic versions of both medications.

NEXLETOL contains bempedoic acid, while NEXLIZET combines bempedoic acid with ezetimibe. Both are oral, once-daily treatments for patients with elevated low-density lipoprotein cholesterol

Esperion settles with fifth generic drug maker over cholesterol patents

Tue, 17 Feb 2026 08:00:54 -0400

NEXLETOL contains bempedoic acid, while NEXLIZET combines bempedoic acid with ezetimibe. Both are oral, once-daily treatments for patients with elevated low-density lipoprotein cholesterol

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Tue, 17 Feb 2026 08:00:00 -0400

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included